CJC-1295: an unfinished clinical file
A peptide built to last in blood. A patient trial that stopped. The hormone findings impress me; the clinical history leaves a harder question.
The albumin attachment
The cleverness of CJC-1295 is in its attachment. It copies the active fragment of growth-hormone-releasing hormone, or GHRH, the signal that prompts the pituitary gland to release growth hormone. Four changes to its amino-acid chain slow breakdown; the DAC version adds a chemical tether to albumin, a protein already circulating in blood. Jette and colleagues tested that albumin-binding design in rats and a cell-free enzyme assay.
I admire the albumin tether. Borrowing a circulating protein as a carrier is an economical answer to a peptide that would otherwise disappear quickly. In healthy adults, the estimated half-life reached 5.8–8.1 days. Half-life is the time for the measured amount to fall by half, so the figure describes persistence, while the question of useful treatment still requires patient outcomes.
CJC-1295 peptide searches often bring both DAC and no-DAC material into the same conversation. The form comparison identifies Modified GRF (1-29) as the short-acting counterpart without the albumin attachment. The distinction deserves its own page: CJC-1295 DAC vs no DAC concerns molecular identity as well as timing.
From healthy volunteers to a patient trial
The early human work established a substantial hormone response. In Teichman and colleagues’ healthy-adult studies, growth hormone and IGF-1—the liver’s downstream growth signal— rose for days. The later pulsatility study found that growth hormone’s natural bursts continued even as its between-burst level increased.
The development programme then reached patients with HIV-associated visceral obesity, meaning excess fat deep in the abdomen. ConjuChem’s Phase 2 trial was discontinued. The public history includes a reported patient death during development, with causation unresolved. It supplies neither a demonstrated long-term benefit nor a completed safety record.
I expected the patient study to carry the story forward. Instead, it leaves the clinical file open at the point where the hormone findings most needed a health outcome. That unfinished step is why MD CJC-1295 exists.
The later papers follow a different trail
There is an unusual sequel. In the 2010 paper, analysts identified CJC-1295 in an unknown preparation seized in an anti-doping context. Subsequent papers developed blood-based identification methods and an antibody-free assay for GHRH analogs; a later paper studied GHRH analogs in urine.
To me, the persistence of the detection work makes the unfinished clinical work more conspicuous. Laboratories continued to refine ways of finding these compounds. The large, long-term efficacy trials in healthy adults are still missing from the published record. A review of approved and unapproved peptide therapies puts that evidence gap in the wider musculoskeletal context.
CJC-1295 remains an unapproved research compound. It is also prohibited in sport at all times under WADA Section S2. Those are concrete parts of the file, alongside the chemistry and the human measurements.
The file index
The human research follows the volunteer measurements and their quieter details. DAC vs no DAC separates the long-acting molecule from the short-acting name used online.
Sleep and recovery reports cover the experiences people describe, while side effects examines the safety questions those reports cannot count. The study amounts remain attached to their experiments.
For a laboratory document or a rules question, the FAQ covers test reports and legal status. The reading list contains the original papers and regulatory records.